NCT02515695View on ClinicalTrials.gov

Phase I BP Interferon (IFN) Beta-001

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Interferon beta-1a

6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution

Sponsors

Collaborators (1)

BioPartners GmbH

All Listed Sponsors

collaborator

BioPartners GmbH

INDUSTRY

lead

Centre Hospitalier Universitaire Vaudois

OTHER

NCT02515695 - Phase I BP Interferon (IFN) Beta-001 | Biotech Hunter | Biotech Hunter